OMERS ADMINISTRATION Corp Acquires New Shares in Halozyme Therapeutics, Inc. $HALO

Key Points

• OMERS Administration Corp. acquired 47,989 Halozyme shares worth approximately $3.76 million during the second quarter. Institutional investors collectively own 97.79% of the company.
• Halozyme reported quarterly EPS of $2.28, beating estimates of $1.79, while revenue rose 47.7% year over year to $481 million. The company issued fiscal 2026 EPS guidance of $8.65–$9.00.
• Analysts maintain a generally positive view, with nine Buy ratings and a consensus “Moderate Buy” rating, although the $91.20 consensus price target is below the stock’s reported $109.32 price. Insiders sold 64,103 shares worth $5.23 million over the past 90 days.

OMERS ADMINISTRATION Corp bought a new position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 47,989 shares of the biopharmaceutical company's stock, valued at approximately $3,756,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Measured Wealth Private Client Group LLC increased its holdings in shares of Halozyme Therapeutics by 51.5% in the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company's stock worth $25,000 after acquiring an additional 124 shares during the period. Larson Financial Group LLC boosted its stake in Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 343 shares during the period. MidFirst Bank acquired a new position in Halozyme Therapeutics during the 2nd quarter valued at about $27,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Halozyme Therapeutics in the 2nd quarter worth about $28,000. Finally, Quantbot Technologies LP bought a new position in Halozyme Therapeutics in the 2nd quarter worth about $30,000. Institutional investors and hedge funds own 97.79% of the company's stock.

Halozyme Therapeutics Trading Up 0.6%

Shares of NASDAQ:HALO opened at $109.32 on Wednesday. The company has a 50 day moving average of $84.73 and a 200-day moving average of $74.19. The company has a current ratio of 2.71, a quick ratio of 2.31 and a debt-to-equity ratio of 13.50. The firm has a market cap of $12.41 billion, a P/E ratio of 32.63, a P/E/G ratio of 0.44 and a beta of 0.85. Halozyme Therapeutics, Inc. has a twelve month low of $61.22 and a twelve month high of $109.55.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating analysts' consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. The business's revenue for the quarter was up 47.7% on a year-over-year basis. During the same quarter last year, the business earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, analysts anticipate that Halozyme Therapeutics, Inc. will post 7.77 earnings per share for the current fiscal year.

Insider Transactions at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total transaction of $167,152.80. Following the transaction, the director directly owned 40,418 shares of the company's stock, valued at $4,154,970.40. The trade was a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total value of $2,083,600.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $79,987,320.40. The trade was a 2.54% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 64,103 shares of company stock valued at $5,226,496. Corporate insiders own 2.50% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. HC Wainwright lifted their price target on Halozyme Therapeutics from $95.00 to $115.00 and gave the company a "buy" rating in a report on Friday, August 7th. Wells Fargo & Company increased their price objective on Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an "equal weight" rating in a report on Friday, August 7th. Citizens Jmp raised their target price on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a "market outperform" rating in a research report on Friday, August 7th. Wall Street Zen raised Halozyme Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 8th. Finally, TD Cowen boosted their price target on Halozyme Therapeutics from $96.00 to $105.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Nine equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Halozyme Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $91.20.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company's core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company's flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source